亚太实业(000691) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥104,397,898.74, a decrease of 12.03% compared to ¥118,672,474.76 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥8,928,537.70, representing a decline of 746.78% from a profit of ¥1,380,452.58 in the previous year[5] - The company recorded a net loss of ¥12,506,731.10 for the period, a decline of 386.85% compared to a profit of ¥4,360,096.57 in the previous year[7] - Total operating revenue for Q1 2024 was CNY 104,397,898.74, a decrease of 11.99% compared to CNY 118,672,474.76 in Q1 2023[25] - The total comprehensive income attributable to the parent company was -¥8,928,537.70, compared to ¥1,380,452.58 in the same period last year[30] - Basic and diluted earnings per share for Q1 2024 were both -¥0.0276, a decrease from ¥0.0043 in the previous year[30] Cash Flow and Liquidity - The net cash flow from operating activities increased by 281.23% to ¥10,635,671.63, up from ¥2,789,798.83 in the same period last year[5] - As of March 31, 2024, the company's cash and cash equivalents increased to CNY 49,002,972.38 from CNY 40,694,311.38 at the beginning of the period, reflecting a growth of approximately 31.3%[22] - The total cash and cash equivalents at the end of the period increased to ¥40,999,683.71 from ¥27,589,215.56, representing a growth of 48.5%[30] - The cash outflow from investing activities was -¥1,257,865.18, an improvement from -¥3,147,355.60 in the previous year[30] - The cash flow from financing activities resulted in a net outflow of -¥1,176,933.33, compared to -¥2,531,111.11 in the same period last year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥656,359,782.93, reflecting a growth of 4.25% from ¥629,578,066.31 at the end of the previous year[5] - Total liabilities rose to CNY 473,054,654.79, up from CNY 434,468,182.13, indicating an increase of 8.83%[24] - The company's equity attributable to shareholders decreased to CNY 31,602,327.75 from CNY 40,172,858.16, a decline of 21.36%[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 19,850[8] - The top shareholder, Lanzhou Asia-Pacific Mining Group Co., Ltd., holds 9.95% of shares, totaling 32,177,295 shares, with 26,500,000 shares pledged[8] - Lanzhou Taihua Investment Holding Co., Ltd. owns 6.99% of shares, amounting to 22,583,700 shares, with 21,250,000 shares pledged[8] - Wang Yuqian, a natural person, holds 5.01% of shares, which is 16,200,000 shares[8] - The company plans to issue 96,880,000 shares to specific investors, with Guangzhou Wanshun Technology Co., Ltd. subscribing to all shares, increasing its control from 16.94% to 23.06%[9] - After the issuance, Guangzhou Wanshun will control 36.09% of the voting rights of the company[9] Operational Changes and Expenses - The company experienced a 32.65% increase in management expenses, totaling ¥11,819,376.13, due to an increase in management personnel[7] - Total operating costs increased to CNY 117,399,658.39, up from CNY 113,836,246.64, representing a rise of 4.96%[26] - Research and development expenses were CNY 4,334,682.37, slightly down from CNY 4,367,374.37, a decrease of 0.75%[26] Debt and Guarantees - The company confirmed a claim of ordinary debt amounting to CNY 25,898,305.48 from its subsidiary, Lingang Yano Chemical, against Zhejiang Lanbo Biotechnology Co., Ltd.[13] - The company plans to provide a guarantee for a bank loan of up to CNY 30 million for its subsidiary, with a maximum interest rate of 4.5%[15] - A total of 26,927,295 shares, representing 8.33% of the company's total equity, are subject to forced sale due to debt obligations[20] - The company's major shareholder, Yatai Mining, and its concerted party hold a total of 54,760,995 shares, accounting for 16.94% of the total share capital[20] - 47,750,000 shares, or 87.20% of the shares held by Yatai Mining, have been pledged[20] - 44,427,295 shares, or 81.13% of the shares held by Yatai Mining, have been frozen or marked[20] Regulatory and Compliance - The company received government subsidies amounting to ¥276,214.19, which were closely related to its normal business operations[6] - The company held a shareholder meeting on July 19, 2023, approving a three-year shareholder return plan for 2023-2025[10] - The company received notification from the Shenzhen Stock Exchange on April 19, 2024, regarding the acceptance of its application for issuing shares to specific investors[11] - The issuance of shares is subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the timeline[11] - The company is actively monitoring the operational status of its debtors and will ensure compliance with disclosure obligations[14] - The court has recognized the settlement agreement proposed by Zhejiang Lanbo Biotechnology, concluding the reconciliation process[14] - The company will continue to fulfill its information disclosure obligations regarding the ongoing bankruptcy case of its subsidiary's debtors[14]